Monogram Technologies (NASDAQ: MGRM) is a medical device company developing a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. On 5/17/25, the company received clearance from the FDA on its 510(k) submission for its mB s TKA System. The first live in patient surgery OUS is expected in early 2025. The company has $15.7 million in cash after the recent equity offering. We believe MGRM stock to be undervalued at this time with several significant potential catalysts within the next 12 months.
